We are live on ! Find out more
BLAM

Bourne Lent Asset Management Portfolio holdings

AUM $289M
1-Year Est. Return 30.86%
This Fund
S&P 500
This Quarter Est. Return
+12.22%
1 Year Est. Return
+30.86%
3 Year Est. Return
+76.09%
5 Year Est. Return
+95.46%
10 Year Est. Return
+670.42%
AUM
$212M
AUM Growth
+$3.81M
Cap. Flow
-$14.4M
Cap. Flow %
-6.8%
Top 10 Hldgs %
75.52%
Holding
61
New
5
Increased
12
Reduced
13
Closed
1

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$23.8M
2
ENB icon
Enbridge
ENB
+$503K
3
LHX icon
L3Harris
LHX
+$501K
4
AMZN icon
Amazon
AMZN
+$443K
5
ILMN icon
Illumina
ILMN
+$405K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$41.3M
2
IDXX icon
Idexx Laboratories
IDXX
+$174K
3
GE icon
GE Aerospace
GE
+$152K
4
VZ icon
Verizon
VZ
+$124K
5
PFE icon
Pfizer
PFE
+$119K

Sector Composition

Rank Sector Weight
1 Technology 40.99%
2 Healthcare 33.84%
3 Communication Services 10.02%
4 Consumer Discretionary 4.46%
5 Industrials 3.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LHX icon
26
L3Harris
LHX
$53.6B
$940K 0.44%
4,750
+2,500
+111% +$501K
PEG icon
27
Public Service Enterprise Group
PEG
$37.4B
$893K 0.42%
15,122
– –
BSX icon
28
Boston Scientific
BSX
$69.3B
$804K 0.38%
17,789
– –
VZ icon
29
Verizon
VZ
$190B
$804K 0.38%
13,100
-2,050
-14% -$124K
INTC icon
30
Intel
INTC
$498B
$771K 0.36%
12,890
– –
PEP icon
31
PepsiCo
PEP
$189B
$769K 0.36%
5,625
– –
ILMN icon
32
Illumina
ILMN
$30.3B
$730K 0.34%
2,262
+1,337
+145% +$405K
LLY icon
33
Eli Lilly
LLY
$1.04T
$690K 0.33%
5,253
– –
MRK icon
34
Merck
MRK
$323B
$606K 0.29%
6,987
– –
VAR
35
DELISTED
Varian Medical Systems, Inc.
VAR
$482K 0.23%
3,390
– –
BA icon
36
Boeing
BA
$188B
$465K 0.22%
1,428
– –
CNP icon
37
CenterPoint Energy
CNP
$26.6B
$463K 0.22%
16,966
-300
-2% -$8.16K
MCHP icon
38
Microchip Technology
MCHP
$42.2B
$431K 0.2%
8,230
– –
LOW icon
39
Lowe's Companies
LOW
$123B
$419K 0.2%
3,500
– –
EOG icon
40
EOG Resources
EOG
$72.8B
$406K 0.19%
4,851
– –
SLB icon
41
SLB Ltd
SLB
$74.8B
$368K 0.17%
9,150
-1,850
-17% -$66.1K
GILD icon
42
Gilead Sciences
GILD
$163B
$354K 0.17%
+5,455
New +$355K
BNY
43
Bank of New York Mellon
BNY
$108B
$352K 0.17%
7,000
– –
CTSH icon
44
Cognizant
CTSH
$25.1B
$329K 0.16%
5,300
– –
HD icon
45
Home Depot
HD
$351B
$317K 0.15%
1,450
– –
SYK icon
46
Stryker
SYK
$128B
$315K 0.15%
1,500
– –
XOM icon
47
ExxonMobil
XOM
$629B
$312K 0.15%
4,470
– –
PG icon
48
Procter & Gamble
PG
$340B
$286K 0.13%
2,291
– –
HRL icon
49
Hormel Foods
HRL
$13.9B
$284K 0.13%
6,295
– –
WU icon
50
Western Union
WU
$2.3B
$267K 0.13%
9,988
– –
1
2
3

Similar funds

PIA
PineBridge Investments Asia Hong Kong $289M AUM
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
GIM
Goodlander Investment Management Dallas, Texas $289M AUM 225.62% 1-Year Est. Return
PSA
Plum Street Advisors New Orleans, Louisiana $289M AUM 17.28% 1-Year Est. Return
SI
Saxon Interests Houston, Texas $290M AUM 19.97% 1-Year Est. Return
LK
Lumbard & Kellner Hollis, New Hampshire $289M AUM 59.5% 1-Year Est. Return
FFA
Fairfield Financial Advisors Wellesley, Massachusetts $290M AUM 15.81% 1-Year Est. Return
OCM
Orion Capital Management Coronado, California $290M AUM 17.97% 1-Year Est. Return

Bourne Lent Asset Management's Q4 2019 Portfolio in Review

As of Q4 2019, Bourne Lent Asset Management held 61 positions worth $212M, up 1.8% from $209M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Bourne Lent Asset Management withdrew a net $14.4M in Q4 2019, closing 1 position and reducing 13 holdings. Its most notable exit was Celgene Corp, an estimated $41.3M position sold in full.

By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 36% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, Bourne Lent Asset Management opened a new position in Gilead Sciences worth $354K.

  • Bourne Lent Asset Management's largest Q4 2019 buy was Gilead Sciences: 5,455 shares worth $354K.
  • Bourne Lent Asset Management added most to Bristol-Myers Squibb in Q4 2019, an estimated $23.8M increase.
  • Bourne Lent Asset Management's biggest Q4 2019 reduction was Idexx Laboratories, cutting an estimated $174K.
  • Bourne Lent Asset Management fully exited Celgene Corp in Q4 2019, selling an estimated $41.3M.
  • Bourne Lent Asset Management's ten largest holdings make up 76% of its $212M portfolio in Q4 2019.
  • Bourne Lent Asset Management opened 5 new positions and closed 1 in Q4 2019.
  • Bourne Lent Asset Management's portfolio value rose 1.8% quarter-over-quarter to $212M.

Based on Bourne Lent Asset Management's 13F filing for Q4 2019, filed 24 Jan 2020.